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Abstract
We report the presence of SNPs in Plasmodium falciparum K13-propeller gene in two Afri-
can countries, Angola and Mozambique, where malaria is a serious public health problem.
Samples were collected before and after ACT introduction as first-line treatment. In each
country 50 samples collected before and 50 after ACT introduction were analysed. A total of
three different mutations (R471R and R575R in Angola and V494I in Mozambique) were
identified in five samples, all collected after the introduction of ACT. The R471R mutation
detected in Angola has already been reported in Africa (DR-Congo and Gabon). However,
the mutations R575R (Angola) and V494I (Mozambique), have never been reported. V494I
is adjacent to the known K13 resistance-associated mutation Y493H, although functional
analysis did not predict a deleterious effect on protein function.
Introduction
The emergence of artemisinin resistance is of great concern since the current first-line treat-
ment for Plasmodium falciparummalaria in endemic countries relies on artemisinin-based
combination therapies (ACT) [1]. Partial artemisinin resistance has been defined as a slower
parasite clearance rate following treatment with an artesunate monotherapy, or after treatment
with an (ACT) [1] and is increasingly common in South East Asia. Nevertheless this definition
is affected by multiple factors such as patient immunity, blood drug concentration or partner
drug activity [1]. Clinical response to ACT treatments (treatment failures) reflects the efficacy
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of both drugs in the combination, being the proportion of patients remaining parasitemic on
day 3 the indicator of choice, currently used in routine monitoring for suspected artemisinin
resistance [1]. Treatment failures observed in South East Asia correlate either with lower effica-
cy of the partner drug and with slower parasite clearance rate due to artemisinin partial resis-
tance [2]. Historical evidence shows that the emergence of drug-resistant (chloroquine and
sulphadoxine-pyrimethamine) P. falciparum strains first occurred in Southeast Asia, spread to
East Africa and then spread outwards to the rest of the African continent [3].
During the last decade, African countries have gradually changed first-line treatment for
uncomplicated falciparummalaria to ACT due to the development of resistance to the succes-
sively introduced anti-malarial drugs. In 2002, Mozambique (East Africa) replaced chloroquine
by sulphadoxine-pyrimethamine in combination with amodiaquine (AQ-SP); in 2004 artesu-
nate substituted AQ (AS-SP) and since 2009, this combination changed to artemether-lume-
fantrine [4]. In Angola (West Africa), the artesunate-amodiaquine combination was officially
adopted in 2004, followed by artemether-lumefantrine in 2006 [5] and ACTs have been used
nationwide since 2007.
In 2014, Ariey et al. [6] associated the artemisinin resistant phenotype to mutations on the
kelch propeller protein K13 encoded in PF3D7_1343700 gene. In Cambodia, where these poly-
morphisms were first described, the presence of K13 mutants (mainly Y493H, R539T, I543T
and C580Y) are correlated to in vitro parasite survival rates and in vivo parasite clearance rates.
In August 2014, the World Health Organization included K13 mutations in the new working
definition for partial artemisinin resistance stating that the presence of5% of patients carry-
ing K13 resistance-associated single nucleotide polymorphisms (SNPs) defines suspected arte-
misinin resistance; when K13 mutants are associated with either persistent parasitemia on day
3 or longer parasite clearance, resistance is confirmed [1].
K13-propeller SNPs have been searched in multiple locations aiming to describe the pres-
ence of resistant parasites before clinical resistance spreads, following the recommendations of
WHO. To date, more than 60 mutations in K13 gene have been described in Africa and South
East Asia [2,6,7–10], however, no resistance-associated mutations have been found outside the
Greater Mekong Area [1].
In this study we report the presence of polymorphisms in P. falciparum K13-propeller in
Angola and Mozambique, two portuguese-speaking countries endemic for malaria, before and
after the introduction of ACT as first-line treatment.
Methods
Ethics statement
DNA samples were collected following individual oral consent and signed informed written
consent from all participants or their guardians. Ethics approval to use the samples was ob-
tained from: Comité de Ética do Ministério de Saúde de Angola (Committee of Ethics of the
Ministry of Health of Angola), Comité de Ética do Hospital Pediátrico Dr. David Bernardino
(Committee of Ethics of the Pediatric Hospital Dr. David Bernardino in Luanda Angola) and
Comité Nacional de Bioética para a Saúde (CNBS) from the do Ministy of Health of
Mozambique.
A set of 200 DNA samples from P. falciparum-infected individuals, already available from
other studies [11–13], were analysed. Four groups of samples (50 each) from Angola and Mo-
zambique, corresponding to time periods before and after the official introduction of ACT as
the first-line treatment of malaria in both countries. In Angola, samples were collected during
2003 and during 2010. In Mozambique, one set of samples was collected between June 2003
and June 2005 and another set of samples between March 2010 and March 2012. All ethical
K13 Mutations in Angola and Mozambique
PLOS ONE | DOI:10.1371/journal.pone.0119215 March 19, 2015 2 / 6
2011 - Proj. Estratégico LA0018 2011/2012 (more
information available at: http://cmdt.ihmt.unl.pt/index.
php/pt/). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: Ana Paula Arez is a PLOS
ONE Editorial Board member, but she is not the
editor of the manuscript consequently, this does not
alter the authors’ adherence to PLOS ONE Editorial
policies and criteria. The authors declare that after
carefully reviewing the PLOS ONE website details on
competing interests, the authors have not detected
any potential competing interests, for the purposes of
transparency in the content or process of submission
of the presented manuscript.
aspects related with the sets of samples are described in the respective reports [11–13]. Samples
were conserved as extracted DNA frozen at -20°c at Instituto de Higiene e Medicina Tropical in
Lisbon (Portugal). A 520bp region (corresponding to codons 460 to 592) of PF3D7_1343700
gene was amplified by PCR. This region covered the region of the gene were the previously de-
scribed SNPs associated with artemisinin resistance are located [6] and included in WHO defi-
nition [1] allowing the identification of the referred SNPs in one sequencing run.
Specific primers were developed for this purpose (forward—GTGTAGAATATT-
TAAATTCG; reverse—GCTCCTGAACTTCTAGCTTC). An aliquot of the PCR products
were analyzed by electrophoresis on a 2% agarose gel stained with ethidium bromide to con-
firm amplification. A second semi-nested procedure was performed in some samples, obtain-
ing a fragment of 445bp (reverse primer—GCTCCTGAACTTCTAGCTTC). Products were
sequenced at STAB VIDA Genomics LAB, Caparica, Portugal) and aligned to 3D7 reference
strain using Multalin software (http://multalin.toulouse.inra.fr/; free online). Samples were
SNPs were detected underwent new PCR amplification and sequencing procedure to ascertain
the results. The genotype data used in the analysis have been submitted to the National Center
for Biotechnology Information for public access (accession numbers: KP262063, KP262064,
KP262065, KP262066 and KP262067).
In order to predict biological functional relevance for non-synonymous SNPs we used PRO-
VEAN software tool (http://provean.jcvi.org/; free online). This software is validated to predict
whether a protein sequence variation (substitution, deletion or insertion of single or multiple
amino acid) affects protein function in human and non-human proteins on an homology-
based approach. The algorithm uses a sequence homolog collected from the NCBI database
through BLAST. In our study human KEAP1 protein was used as reference (PDB ID: 3VNG)
as previously described by Ariet et al. [6]. PROVEAN algorithm assumes a score of-2.5 as cut-
off for a binary neutral/deleterious function classification with a sensitivity of 80.4% and a spec-
ificity of 78.6%.
Results
P. falciparum K13-propeller polymorphisms observed
A total of 3 different mutations (R471R, V494I, R575R) were found in 5 samples (2.5%). All
mutations were found in samples collected after the introduction of ACTs as the official first-
line treatment in each country. Fig. 1 shows geographical origin of the samples and time period,
and Table 1 shows K13-propeller polymorphisms identified.
The newly described polymorphism V494I was found in two samples fromMaputo prov-
ince (Mozambique). Two synonymous polymorphisms (R471R in two samples and R575R in
one sample) were found in Angola. R575R, also newly described, was found in Malanje, an An-
golan province that borders the Democratic Republic of Congo. R471R (found in Luanda and
Malanje) has already been observed in DR Congo (Kinshasa) [9] and Gabon (Libreville) [10].
All polymorphisms were uncommon (R471R 4%, V494I 4%, R575R 2%), and each was present
in different isolates. The mutations associated to artemisinin-resistance (Y493H, R539T, I543T
and C580Y) described in Southeast Asia [2,6] were not detected.
Functional assessment of polymorphisms observed
Using PROVEAN software tool with a cut-off score of-2.5, we predicted that V494I variant
may have a neutral effect on protein biological function (PROVEAN score = -0.774). The same
cut-off for known polymorphisms in K13-propeller predicted a deleterious effect on protein
function for all (Y493H score = -4.166, I543T score = -3.401, and C580Y score = -2.849) except
for R539T which falls right below significance (score = -2,489).
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Discussion
The shift in drug policy in Africa towards ACTs was recent, it has been accompanied by both
the selection of polymorphisms associated with decreased lumefantrine sensitivity [13,14] and
by the decrease of the in vitro sensitivity to this drug [15]. The reduced sensitivity to ACT
Fig 1. P. falciparum K13-propeller polymorphisms prevalence and distribution in Angola and Mozambique. Panel 1) Proportion within each time
period of wild type (wt) and mutant (mut) samples; Panel 2) Geographical location of sample collection (dark grey) and identified polymorphisms.
doi:10.1371/journal.pone.0119215.g001
Table 1. P. falciparum K13-propeller amino acid and nucleotide substitutions observed in Angola and Mozambique.
Locusa.a. Locus Nuc. Ref. codon Mut. codon Country—Region (n)
R471R* 1413 CGT CGC Angola—Malanje (1) & Luanda (1)
V494I 1483 GTT ATT Mozambique—Maputo (2)
R575R 1725 AGA AGG Angola—Malanje (1)
*SNP has been previously observed in DR Congo, Kinshasa [9] and Gabon, Libreville [10]. All data are relative to reference sequence PF3D7_1343700.
Abbreviations: a.a., aminoacid; nuc, nucleotidic; ref, reference; mut, mutated; n, number of samples containing mutant allele.
doi:10.1371/journal.pone.0119215.t001
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partner drugs may increase the selection of artemisinins resistant parasites. Thus, the use of the
new molecular marker K13-propeller is fundamental for surveillance in malaria control pro-
grams, in order to prolong the life span of the ACTs in Africa.
Our study on P. falciparum K13-propeller polymorphisms showed the presence of three
mutations, two of them not previously described. One of the mutations is a non-synonymous
SNP (V494I) that lays one codon next to the known K13 resistance-associated mutation
(Y493H). Although functional analysis for V494I did not predict deleterious effect on protein
function (PROVEAN score = -0,774) as it does for Y493H (score = -4,166), this does not neces-
sarily mean that the protein is not affected. For instance, R539T was considered neutral in a
similar analysis (score = -2,489), although it is associated to ACT drug response in Southeast
Asia [6]. Plus, V494I was identified in two samples collected in Mozambique after the intro-
duction of ACTs. Mozambique is located at East Africa, a region recognized as being a major
focus of drug resistant parasites entrance and development in sub-Saharan Africa, probably
originated at Southeast Asia [3]. While speculative, justifies further attention. The other two
polymorphisms described in our study encode synonymous substitutions, thus not affecting
protein structure and function. Mutation R471R observed in samples collected after ACT in-
troduction in Malanje and Luanda provinces (Angola) has also been reported in two other
western African countries, DR Congo [9] and Gabon [10], however it is difficult to attribute
this to the spread of a P. falciparum clone or to multiple emergence of this SNP. Nevertheless,
parasites in endemic regions of sub-Saharan Africa are less likely to be clonal because of the
high transmission intensity [10]. Recently, K13 resistance-associated mutations have been
demonstrated to arise both population-specific and independently in different geographic
areas in Southeast Asia [2]. Multiple non-synonymous polymorphisms have been published,
but there are very few shared mutant alleles between African and Southeast Asia parasites as
yet [2,6,9].
The absence of K13 resistance-associated mutants from Southeast Asia in Africa [7–10] is
promising, but continuous tracking of resistance emergence should be implemented enabling
early detection of resistant parasites. The use of a molecular marker such as K13 mutations is
nowadays a cornerstone for malaria surveillance programs, but differences between African
and Asian K13-mutant parasites should be taken into account, and this study provides useful
information on two not previously described K13 polymorphisms in Angola and Mozambique
where malaria is a serious public health problem.
Whether or not the mutations identified during the present study are associated to drug re-
sponse, can not be inferred from our results (no phenotype of drug resistance was observed in
the mutant carrier samples). Nevertheless, no SNPs were present in the samples collected be-
fore the introduction of the ACTs as a first-line of treatment in each country.
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